(Q30226740)

English

A phase III, randomized, open-label study to assess the tolerability and immunogenicity of an H5N1 influenza vaccine administered to healthy adults with a 1-, 2-, 3-, or 6-week interval between first and second doses

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

11 June 2017

A phase III, randomized, open-label study to assess the tolerability and immunogenicity of an H5N1 influenza vaccine administered to healthy adults with a 1-, 2-, 3-, or 6-week interval between first and second doses (English)

1 reference

Europe PubMed Central

11 June 2017

influenza vaccine

1 reference

based on heuristic

inferred from title

author name string

Jiri Beran

1

1 reference

Europe PubMed Central

11 June 2017

Ibrahim A Abdel-Messih

2

1 reference

Europe PubMed Central

11 June 2017

Jolana Raupachova

3

1 reference

Europe PubMed Central

11 June 2017

Lenka Hobzova

4

1 reference

Europe PubMed Central

11 June 2017

Elena Fragapane

5

1 reference

Europe PubMed Central

11 June 2017

publication date

1 December 2010

1 reference

Europe PubMed Central

11 June 2017

Clinical Therapeutics

1 reference

Europe PubMed Central

11 June 2017

32

1 reference

Europe PubMed Central

11 June 2017

13

1 reference

Europe PubMed Central

11 June 2017

2186-2197

1 reference

Europe PubMed Central

11 June 2017

Establishment of multiple sublineages of H5N1 influenza virus in Asia: Implications for pandemic control

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900024-5

7 January 2021

based on heuristic

inferred from DOI database lookup

How prepared is Europe for pandemic influenza? Analysis of national plans

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900024-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Vaccines against avian influenza--a race against time

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900024-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Avian influenza vaccines: what's all the flap?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900024-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Influenza pandemic preparedness: gauging from EU plans

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900024-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Development and evaluation of influenza pandemic vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900024-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Highly pathogenic avian influenza H5N1, Thailand, 2004

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900024-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Avian influenza A (H5N1) in 10 patients in Vietnam

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900024-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Probable person-to-person transmission of avian influenza A (H5N1)

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900024-5

7 January 2021

based on heuristic

inferred from DOI database lookup

H5N1 influenza--continuing evolution and spread

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900024-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Selection of influenza vaccine strains and developing pandemic vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900024-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Strategies for mitigating an influenza pandemic

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900024-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900024-5

7 January 2021

based on heuristic

inferred from DOI database lookup

MF59-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900024-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900024-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Humoral and cellular immune responses to split-virion H5N1 influenza vaccine in young and elderly adults.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900024-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900024-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900024-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900024-5

7 January 2021

based on heuristic

inferred from DOI database lookup

MF59-adjuvanted vaccines: increased immunogenicity with an optimal safety profile

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900024-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900024-5

7 January 2021

based on heuristic

inferred from DOI database lookup

MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900024-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and immunogenicity of nonadjuvanted and MF59-adjuvanted influenza A/H9N2 vaccine preparations.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900024-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900024-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Confronting the avian influenza threat: vaccine development for a potential pandemic.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900024-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety of MF59 adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900024-5

7 January 2021

based on heuristic

inferred from DOI database lookup

MF59-adjuvanted influenza vaccine (FLUAD) in children: safety and immunogenicity following a second year seasonal vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900024-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900024-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Antigenically distinct MF59-adjuvanted vaccine to boost immunity to H5N1.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900024-5

7 January 2021

based on heuristic

inferred from DOI database lookup

The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2811%2900024-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0149-2918(11)00024-5

1 reference

Europe PubMed Central

11 June 2017

1 reference

Europe PubMed Central

11 June 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30226740&oldid=1948673711"